Zdrowie i gospodarka · 18/10/2022
FDA Releases Draft Guidance for Industry on Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials
The FDA is releasing a draft guidance for industry on how to characterize, collect, and report immune-mediated adverse reactions in cancer immunotherapeutic clinical trials, aiming to improve the assessment of adverse events in cancer treatments.